Breast cancer and hormone-replacement therapy in the Million Women Study

Maturitas

Volumn 46, Issue 2, 2003, Pages 91-92

  Crosignani, P G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE; PREGNANE DERIVATIVE; TIBOLONE;

ADULT; BODY MASS; BREAST CANCER; BREAST TUMOR; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CUTANEOUS PARAMETERS; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG SYNTHESIS; DRUG USE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; IATROGENIC DISEASE; INCIDENCE; LONG TERM CARE; MENOPAUSAL SYNDROME; NOTE; OBESITY; OSTEOLYSIS; PRESCRIPTION; RISK FACTOR; STUDY; TIME; UNITED KINGDOM; WEIGHT REDUCTION;

EID: 0141957334     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.09.002     Document Type: Note

References (4)

1. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 362:2003;419-427.
2. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomised controlled trial. J. Am. Med. Assoc. 288:2002;321-333.
3. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. New Engl. J. Med. 348:2003;1625-1628.
4. Moore R.A. Livial: a review of clinical studies. Br. J. Obstet. Gynaecol. 106:(Suppl. 19):1999;1-21.